Skip to main content
Donald Tsai, MD, Oncology, Philadelphia, PA, Hospital of the University of Pennsylvania

DonaldETsaiMD

Oncology Philadelphia, PA

Hematologic Oncology

Associate Professor, Medicine, Perelman School of Medicine

Dr. Tsai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tsai's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1996 - 2000
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1994 - 1996
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1994

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1995 - 2024

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
    Donald E. Tsai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...
    Donald E. Tsai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers
    Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017

Hospital Affiliations